KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Inventory (2021 - 2025)

Historic Inventory for Novavax (NVAX) over the last 6 years, with Q3 2025 value amounting to $13.5 million.

  • Novavax's Inventory rose 5641.35% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year increase of 5641.35%. This contributed to the annual value of $8.7 million for FY2024, which is 7901.72% down from last year.
  • As of Q3 2025, Novavax's Inventory stood at $13.5 million, which was up 5641.35% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Inventory ranged from a high of $256.3 million in Q2 2022 and a low of $8.6 million during Q3 2024
  • Over the past 5 years, Novavax's median Inventory value was $19.6 million (recorded in 2023), while the average stood at $46.0 million.
  • In the last 5 years, Novavax's Inventory soared by 31346.93% in 2022 and then plummeted by 9083.58% in 2023.
  • Novavax's Inventory (Quarter) stood at $8.9 million in 2021, then skyrocketed by 313.47% to $36.7 million in 2022, then rose by 13.67% to $41.7 million in 2023, then crashed by 79.02% to $8.7 million in 2024, then surged by 54.43% to $13.5 million in 2025.
  • Its last three reported values are $13.5 million in Q3 2025, $10.2 million for Q2 2025, and $10.3 million during Q1 2025.